Stockscreener 앱 받기
2.38
0.85%
0.02
시간 외 거래:
2.37
-0.010
-0.42%
전일 마감가:
$2.36
열려 있는:
$2.34
하루 거래량:
681.89K
Relative Volume:
0.57
시가총액:
$191.76M
수익:
$52.74M
순이익/손실:
$-6.60M
주가수익비율:
-28.17
EPS:
-0.0845
순현금흐름:
$-13.63M
1주 성능:
+5.78%
1개월 성능:
-15.90%
6개월 성능:
-4.42%
1년 성능:
-9.16%
1일 변동 폭
$2.34
$2.385
1주일 범위
$2.185
$2.385
52주 변동 폭
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
명칭
Protalix BioTherapeutics Inc.
전화
972 4 988 9488
주소
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.38 | 190.15M | 52.74M | -6.60M | -13.63M | -0.0845 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-17 | 재확인 | Rodman & Renshaw | Buy |
| 2016-04-04 | 개시 | Rodman & Renshaw | Buy |
| 2015-04-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2014-11-12 | 재확인 | R. F. Lafferty | Buy |
| 2014-01-24 | 개시 | R. F. Lafferty | Buy |
| 2012-05-02 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | 재확인 | Oppenheimer | Outperform |
| 2012-04-30 | 다운그레이드 | Auriga | Buy → Hold |
| 2011-10-13 | 개시 | Morgan Joseph | Hold |
| 2011-03-17 | 다운그레이드 | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | 재확인 | Oppenheimer | Outperform |
| 2010-10-14 | 재확인 | UBS | Buy |
| 2009-12-02 | 재확인 | Hapoalim | Outperform |
| 2009-09-22 | 개시 | Canaccord Adams | Buy |
| 2009-09-02 | 개시 | Hapoalim | Outperform |
| 2008-12-01 | 재확인 | Oppenheimer | Outperform |
| 2008-03-11 | 개시 | UBS | Buy |
| 2007-11-20 | 개시 | CIBC Wrld Mkts | Sector Outperform |
모두보기
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
Protalix: Elfabrio Struggles Against Oral Competition (NYSE:PLX) - Seeking Alpha
Aug Chart Watch: Is Protalix BioTherapeutics Inc currently under institutional pressure2026 Growth vs Value & Fast Moving Stock Watchlists - baoquankhu1.vn
PLX Stock Price, Quote & Chart | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Targets Report: What is Protalix BioTherapeutics Incs valuation compared to sectorIPO Watch & Risk Controlled Daily Trade Plans - baoquankhu1.vn
PLX Technical Analysis & ETF Price Forecast - Intellectia AI
EBIT per share of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
PLX SEC FilingsProtalix Biother 10-K, 10-Q, 8-K Forms - Stock Titan
Protalix Earnings Call: EU Win, Cash Boost, Trade-Offs - The Globe and Mail
PLX|Protalix Biotherapeutics Inc|Price:2.150|Chg%:-0.04 - TradingKey
MACD Signal: Is Protalix BioTherapeutics Inc a top pick in the sector2026 Trading Volume Trends & Weekly High Return Forecasts - baoquankhu1.vn
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115 - MSN
MAK Capital, Michael Kaufman report 3.62M‑share PLX stake (PLX) - Stock Titan
Aug Opening: What is Protalix BioTherapeutics Incs valuation compared to sector2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Volume Summary: Will Protalix BioTherapeutics Inc benefit from rising consumer demandPortfolio Risk Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Analyst Downgrade: Should I add Protalix BioTherapeutics Inc stock to my portfolio2026 Top Gainers & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX) - Seeking Alpha
Zacks Research Has Bullish Estimate for PLX FY2026 Earnings - MarketBeat
HC Wainwright Issues Negative Outlook for PLX Earnings - marketbeat.com
Can Protalix BioTherapeutics Inc lead its sector in growth2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
If You Invested $1,000 in Protalix Biother (PLX) - Stock Titan
A Look At Protalix BioTherapeutics (PLX) Valuation After Elfabrio Dosing Approval And Updated 2026 Revenue Guidance - Sahm
Research Analysts Issue Forecasts for PLX FY2026 Earnings - MarketBeat
Stock Market Recap: Is Cirrus Logic Inc forming a bullish divergenceRate Hike & High Win Rate Trade Alerts - baoquankhu1.vn
PLX: HC Wainwright & Co. Reiterates Buy Rating with $12 Target | - GuruFocus
Protalix BioTherapeutics (NYSE:PLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 Results - simplywall.st
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlig - GuruFocus
PLX: 2025 Full Year Results - Yahoo Finance
Protalix BioTherapeutics (PLX) Misses Earnings Estimates, Projec - GuruFocus
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - Finviz
Protalix: Overview of Fourth Quarter Financial Results - Bitget
Protalix (PLX) 2025 10-K details Elfabrio expansion and PRX-115 gout program - Stock Titan
Protalix BioTherapeutics 2025 Annual Report: Innovative Plant Cell-Based Therapeutics, Pipeline, Intellectual Property, and Regulatory Overview - Minichart
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 By Investing.com - Investing.com South Africa
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 - Yahoo Finance
PLX: EU approval of Elfabrio's four-week dosing drives revenue growth and strengthens cash position - TradingView
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 - Investing.com
Recap Report: Can Protalix BioTherapeutics Inc keep up with sector leaders2026 Technical Overview & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Protalix BioTherapeutics Financial Results: Quarterly & Annual ReportNews and Statistics - IndexBox
Protalix BioTherapeutics 2025 10-K: $52.7M Revenue, $(6.6)M Net Loss - TradingView
PLX: 2025 revenue reached $52.7M with a net loss of $6.6M as R&D spending increased sharply - TradingView
Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results - TradingView
Protalix: Q4 Earnings Snapshot - marketscreener.com
PLX: 2025 net loss of $6.6M on $52.7M revenue; 2026 revenue outlook $78–83M with pipeline progress - TradingView
Protalix reports FY2025 results: $52.7M revenue, $6.6M net loss, Q2 2026 EU dosing approval - TradingView
Protalix (PLX) swings to 2025 net loss as R&D spend climbs and assets grow - Stock Titan
Earnings Preview: PLX to Report Financial Results Pre-market on March 18 - 富途牛牛
Protalix BioTherapeutics Earnings Announcement Scheduled - Intellectia AI
Can Protalix BioTherapeutics Inc sustain its profitabilityMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - Finviz
Protalix BioTherapeutics Inc. (PLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):